 MENLO PARK, Calif. and SINGAPORE, Oct. 14, 2021 GLOBE NEWSWIRE -- ASLAN Pharmaceuticals Nasdaq: ASLN, a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointments of Dr Melinda Jennifer Gooderham, MSc MD FRCPC, Dr Jacob Thyssen, MD PhD DmSci, and Associate Professor Peter Foley, BMedSci MBBS MD FACD, as members of its Scientific Advisory Board SAB. 